These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4073850)

  • 21. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
    Halliday GM; Macdonald V; Henderson JM
    Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
    Hartmann A; Hunot S; Hirsch EC
    Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
    [No Abstract]   [Full Text] [Related]  

  • 23. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India.
    Muthane U; Yasha TC; Shankar SK
    Ann Neurol; 1998 Mar; 43(3):283-7. PubMed ID: 9506543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degeneration of dopaminergic neurons triggers an expression of individual enzymes of dopamine synthesis in non-dopaminergic neurons of the arcuate nucleus in adult rats.
    Ershov PV; Ugrumov MV; Calas A; Krieger M; Thibault J
    J Chem Neuroanat; 2005 Jul; 30(1):27-33. PubMed ID: 15935614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inducible expression of tryptophan hydroxylase without serotonin synthesis in hypothalamic dopaminergic neurons.
    Vanhatalo S; Soinila S
    Exp Neurol; 1999 Jun; 157(2):305-16. PubMed ID: 10364442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.
    Uhl GR
    Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349
    [No Abstract]   [Full Text] [Related]  

  • 31. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease.
    Goto S; Hirano A
    Ann Neurol; 1991 Aug; 30(2):192-6. PubMed ID: 1680303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease.
    Gai WP; Geffen LB; Denoroy L; Blessing WW
    Ann Neurol; 1993 Apr; 33(4):357-67. PubMed ID: 8489206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen deficiency leads to apoptosis in dopaminergic neurons in the medial preoptic area and arcuate nucleus of male mice.
    Hill RA; Pompolo S; Jones ME; Simpson ER; Boon WC
    Mol Cell Neurosci; 2004 Dec; 27(4):466-76. PubMed ID: 15555924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Morphologic changes in the myelin-poor hypothalamus in involution and senescence in relation to the involution of the gonads].
    Ule G
    Z Gerontol; 1983; 16(4):174-6. PubMed ID: 6356663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
    Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degeneration of the centré median-parafascicular complex in Parkinson's disease.
    Henderson JM; Carpenter K; Cartwright H; Halliday GM
    Ann Neurol; 2000 Mar; 47(3):345-52. PubMed ID: 10716254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hypothalamus in Parkinson disease.
    Langston JW; Forno LS
    Ann Neurol; 1978 Feb; 3(2):129-33. PubMed ID: 350130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.